StockData
Oncolytics Biotech Inc logo

Oncolytics Biotech Inc (ONCY) shareholders

ONCYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 10-Q on Nov 13, 2026Score 0/30
$0.38+0.04 (+12.53%)

Close on Nov 17, 2026Market cap $48.77MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
3.1%
4M of 128M shares
Institutional holders
75
74 new, 1 sold out
Net institutional buying
3M
In Q2 2026
Insider trades, 12 months
14 buys · 0 sales
Net bought $363.23K

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Anson Funds Management LP
Joint filing with Anson Management GP LLC (7.00%), Tony Moore (7.00%) and 3 more
7,649,0507.00%13G (passive) amendmentSep 30, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of ONCYValueChange% of portfolio
Marshall Wace, Llp745,3500.58%$708.08K−114,4810.00%
XTX Topco Ltd260,9030.20%$247.83KNew0.00%
Seeds Investor LLC258,3060.20%$245.37KNew0.03%
International Assets Investment Management, LLC201,2600.16%$181.28KNew0.01%
Connective Capital Management, LLC185,7120.15%$176.41KNew0.12%
Goldman Sachs Group Inc169,8980.13%$161.39KNew0.00%
Tocqueville Asset Management L.P.147,0000.12%$139.64KNew0.00%
Everhart Financial Group, Inc.140,8990.11%$133.84KNew0.01%
Susquehanna International Group, Llp134,1290.11%$127.41KNew0.00%
PFG Investments, LLC128,3000.10%$121.87KNew0.00%
Hrt Financial LP126,3250.10%$119.00KNew0.00%
Invesco Ltd.101,1950.08%$96.13KNew0.00%
Doliver Advisors, LP100,0000.08%$94.99KNew0.02%
LPL Financial LLC80,3160.06%$76.29KNew0.00%
Franklin Resources Inc79,8420.06%$75.84KNew0.00%
Cibc World Market Inc.69,3030.05%$65.83KNew0.00%
Geode Capital Management, LLC66,9390.05%$63.59KNew0.00%
Renaissance Technologies LLC62,0100.05%$58.90KNew0.00%
Royal Bank of Canada57,4110.05%$55.00KNew0.00%
Fifth Third Bancorp45,5260.04%$43.25KNew0.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026754M3.1%74 / 01 / 13M0M
Q1 202621M0.7%2 / 00 / 01M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

FundShares% of ONCYValue% of fundAs of
Fidelity Nasdaq Composite Index Fund66,9390.05%$69.62K0.00%May 31, 2026
Victory Extended Market Index Fund13,5060.01%$10.17K0.00%Jul 31, 2026
Blackstone Alternative Multi-Strategy Fund-1,300-0.00%-$1.23K-0.00%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Jared KellyChief Executive Officer, Director114,0500.09%Jun 3, 2026
John Bearden McAdoryChief Operating Officer––Jun 3, 2026
Kirk LookChief Financial Officer287,5150.23%Jun 3, 2026
Allison HagermanChief Technology Officer115,0590.09%Jun 3, 2026
Thomas Charles HeinemanChief Medical Officer282,8180.22%Jun 3, 2026
Andrew AromandoChief Business Officer55,1000.04%Jun 3, 2026
Deborah Margaret BrownDirector109,8510.09%Jun 3, 2026
Stephen C. GloverDirector––Jun 3, 2026
Angela HolthamDirector183,6390.14%Jun 3, 2026
Jonathan RigbyDirector42,7280.03%Jun 3, 2026
Wayne PisanoDirector492,4140.39%Jun 3, 2026
James T. ParsonsDirector41,8490.03%Jun 3, 2026
Bernd R. SeizingerDirector566,9910.44%Jun 3, 2026
Patricia S. AndrewsDirector78,1280.06%Jun 3, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Jared Kelly
Chief Executive Officer, Director
Mar 12, 2026Buy+5,050$0.96$4.85K114,050
James T. Parsons
Director
Mar 11, 2026Buy+10,000$1.03$10.30K41,849
Thomas Charles Heineman
Chief Medical Officer
Feb 12, 2026Buy+12,132$0.83$10.07K282,818
Wayne Pisano
Director
Feb 12, 2026Buy+30,000$0.84$25.20K492,414
Allison Hagerman
VP, Product Development
Feb 12, 2026Buy+10,000$0.83$8.30K115,059
Bernd R. Seizinger
Director
Feb 12, 2026Buy+40,000$0.85$34.00K566,991
Jared Kelly
Chief Executive Officer, Director
Feb 12, 2026Buy+29,500$0.84$24.78K109,000
Patricia S. Andrews
Director
Feb 12, 2026Buy+35,400$0.86$30.44K78,128
Kirk Look
Chief Financial Officer
Feb 12, 2026Buy+12,000$0.84$10.08K287,515
Deborah Margaret Brown
Director
Feb 12, 2026Buy+25,000$0.85$21.25K109,851
Andrew Aromando
Chief Business Officer
Feb 11, 2026Buy+29,600$0.86$25.46K55,100
Bernd R. Seizinger
Director
Feb 11, 2026Buy+60,000$0.83$49.80K526,991
Jared Kelly
Chief Executive Officer, Director
Feb 11, 2026Buy+5,600$0.84$4.70K79,500
Bernd R. Seizinger
Director
Jan 16, 2026Buy+100,000$1.04$104.00K466,991

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
–
9M shares short
Days to cover
9.9
At 1M shares a day
Change since last report
-3.8%
From 9M shares
Short volume, 20 days
42.8%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Oncolytics Biotech's stock actually held short. Settlement fails (shares not delivered on time) peaked at 81,223 shares on Oct 14, 2026 over the last 90 days.

See a number that looks wrong?